Richard Béliveau | Academic Influence

Richard Béliveau's AcademicInfluence.com Rankings

Richard Béliveau

Biology

#521

World Rank

#920

Historical Rank

Biochemistry

#138

World Rank

#176

Historical Rank

Neuroscience

#2431

World Rank

#2496

Historical Rank

biology Degrees

Download Badge

Biology

Richard Béliveau's Degrees

PhD Biochemistry Université de Montréal
Masters Biochemistry Université de Montréal
Bachelors Biochemistry Université de Montréal

Why Is Richard Béliveau Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Richard Béliveau is currently the director of the Molecular Medicine Laboratory and a researcher in the Department of Neurosurgery at Notre-Dame Hospital. Additionally, he holds the Claude-Bertrand Chair in Neurosurgery at the Centre hospitalier de l'Université de Montréal.

(See a Problem?)

Richard Béliveau's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Involvement of the low‐density lipoprotein receptor‐related protein in the transcytosis of the brain delivery vector Angiopep‐2 (2008) (441)
Matrix metalloproteinase inhibition by green tea catechins. (2000) (405)
Identification and Design of Peptides as a New Drug Delivery System for the Brain (2008) (358)
Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. (2002) (300)
Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2 (2008) (288)
Hypoxia Promotes Murine Bone‐Marrow‐Derived Stromal Cell Migration and Tube Formation (2003) (287)
Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. (2003) (282)
P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. (1997) (249)
The increase of cGMP by atrial natriuretic factor correlates with the distribution of particulate guanylate cyclase (1985) (223)
Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. (2002) (211)
Inhibition of cancer cell proliferation and suppression of TNF-induced activation of NFkappaB by edible berry juice. (2007) (204)
High transcytosis of melanotransferrin (P97) across the blood–brain barrier (2002) (204)
Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. (2002) (200)
Phosphorylation states of Cdc42 and RhoA regulate their interactions with Rho GDP dissociation inhibitor and their extraction from biological membranes. (2002) (176)
Green tea polyphenol (-)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MT1-MMP-driven migration in glioblastoma cells. (2002) (166)
P‐glycoprotein is localized in caveolae in resistant cells and in brain capillaries (2000) (164)
Src-mediated Tyrosine Phosphorylation of Caveolin-1 Induces Its Association with Membrane Type 1 Matrix Metalloproteinase* (2004) (160)
Expression of matrix metalloproteinases and their inhibitors in human brain tumors (2004) (157)
Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts. (2010) (152)
Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. (2010) (150)
Green tea catechins as novel antitumor and antiangiogenic compounds. (2002) (145)
Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains. (2001) (141)
Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration. (2012) (141)
Multidrug Resistance in Brain Tumors: Roles of the Blood–brain Barrier (2004) (139)
Antiproliferative and antioxidant activities of common vegetables: A comparative study (2009) (139)
Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. (1999) (139)
Delphinidin, a dietary anthocyanidin, inhibits vascular endothelial growth factor receptor-2 phosphorylation. (2006) (139)
Src-dependent Phosphorylation of Membrane Type I Matrix Metalloproteinase on Cytoplasmic Tyrosine 573 (2007) (137)
Role of nutrition in preventing cancer. (2007) (134)
HIF-1α mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma (2003) (132)
Activation of the extracellular signal‐regulated protein kinase (ERK) cascade by membrane‐type‐1 matrix metalloproteinase (MT1‐MMP) (2001) (131)
Differential regulation of matrix metalloproteinase activities in abdominal aortic aneurysms. (2002) (129)
Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. (2009) (128)
Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. (2005) (126)
Dexamethasone modulation of multidrug transporters in normal tissues (1999) (121)
High levels of P-glycoprotein detected in isolated brain capillaries. (1993) (121)
Localization of RhoA GTPase to endothelial caveolae-enriched membrane domains. (1998) (112)
Isolation of endothelial cells from brain, lung, and kidney: expression of the multidrug resistance P-glycoprotein isoforms. (2001) (110)
The expression of Rho proteins decreases with human brain tumor progression: Potential tumor markers (2004) (106)
New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. (2010) (104)
Membrane type 1-matrix metalloproteinase (MT1-MMP) cooperates with sphingosine 1-phosphate to induce endothelial cell migration and morphogenic differentiation. (2004) (104)
P‐glycoprotein in blood–brain barrier endothelial cells: interaction and oligomerization with caveolins (2003) (103)
Interaction of drugs with P-glycoprotein in brain capillaries. (1995) (98)
Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. (1996) (97)
The flavonols quercetin, kaempferol, and myricetin inhibit hepatocyte growth factor-induced medulloblastoma cell migration. (2009) (95)
Membrane-Type 1 Matrix Metalloproteinase Stimulates Cell Migration through Epidermal Growth Factor Receptor Transactivation (2007) (91)
Colorectal Cancer Prevention Through Dietary and Lifestyle Modifications (2011) (91)
A MT1-MMP/NF-κB signaling axis as a checkpoint controller of COX-2 expression in CD133(+) U87 glioblastoma cells (2009) (88)
The in situ size of the dopamine transporter is a tetramer as estimated by radiation inactivation. (1994) (85)
Inhibition of HuR and MMP-9 expression in macrophage-differentiated HL-60 myeloid leukemia cells by green tea polyphenol EGCg. (2007) (84)
Expression of multidrug‐resistance P‐glycoprotein (MDR1) in human brain tumors (2001) (83)
The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. (2009) (79)
Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1 (2011) (79)
Cellular localization of P-glycoprotein in brain versus gonadal capillaries. (1996) (76)
Modulation of p‐glycoprotein function by caveolin‐1 phosphorylation (2006) (76)
Tumor Environment Dictates Medulloblastoma Cancer Stem Cell Expression and Invasive Phenotype (2008) (76)
P-glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo PAMPA model. (2009) (74)
Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. (2014) (74)
Ischemia injury alters endothelial cell properties of kidney cortex: stimulation of MMP-9. (2005) (72)
Modulation of invasive properties of CD133(+) glioblastoma stem cells: A role for MT1‐MMP in bioactive lysophospholipid signaling (2009) (71)
Tyrosine phosphorylation of the vascular endothelial-growth-factor receptor-2 (VEGFR-2) is modulated by Rho proteins. (2000) (70)
Hyaluronan Cell Surface Binding Is Induced by Type I Collagen and Regulated by Caveolae in Glioma Cells* (2004) (67)
Induction of medulloblastoma cell apoptosis by sulforaphane, a dietary anticarcinogen from Brassica vegetables. (2004) (67)
Probing the infiltrating character of brain tumors: inhibition of RhoA/ROK‐mediated CD44 cell surface shedding from glioma cells by the green tea catechin EGCg (2005) (67)
Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. (2001) (67)
Emerging concepts in the regulation of membrane-type 1 matrix metalloproteinase activity. (2010) (65)
Matrix metalloproteinase regulation of sphingosine-1-phosphate-induced angiogenic properties of bone marrow stromal cells. (2003) (65)
Regulation of plasminogen activation: a role for melanotransferrin (p97) in cell migration. (2003) (64)
Diet-derived polyphenols inhibit angiogenesis by modulating the interleukin-6/STAT3 pathway. (2012) (64)
The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. (2002) (63)
Purification and characterization of metabolically active capillaries of the blood-brain barrier. (1991) (63)
HIF-1alpha mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma. (2003) (62)
Olive oil compounds inhibit vascular endothelial growth factor receptor-2 phosphorylation. (2014) (61)
Transport characteristics of a novel peptide platform for CNS therapeutics (2009) (60)
The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. (2002) (60)
Neovastat--a novel antiangiogenic drug for cancer therapy. (2003) (59)
Inhibition of melanoma brain metastasis by targeting melanotransferrin at the cell surface (2009) (59)
The Survivin-mediated radioresistant phenotype of glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol (−)-epigallocatechin-3-gallate (2006) (58)
Delphinidin, a dietary anthocyanidin, inhibits platelet-derived growth factor ligand/receptor (PDGF/PDGFR) signaling. (2008) (56)
Cisplatin induces renal expression of P-glycoprotein and canalicular multispecific organic anion transporter. (1999) (55)
Anthocyanidins inhibit migration of glioblastoma cells: Structure‐activity relationship and involvement of the plasminolytic system (2007) (54)
Down‐regulation of protein l‐isoaspartyl methyltransferase in human epileptic hippocampus contributes to generation of damaged tubulin (2002) (54)
Rapid activation of matrix metalloproteinase-2 by glioma cells occurs through a posttranslational MT1-MMP-dependent mechanism. (2000) (54)
Radiation Induced-Tubulogenesis in Endothelial Cells is Antagonized by the Antiangiogenic Properties of Green Tea Polyphenol (-) Epigallocatechin-3-Gallate (2003) (54)
Identification and localization of ATP-diphosphohydrolase (apyrase) in bovine aorta: relevance to vascular tone and platelet aggregation. (1991) (53)
Diallyl disulfide, a chemopreventive agent in garlic, induces multidrug resistance-associated protein 2 expression. (2004) (52)
Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin (2005) (52)
Green tea: prevention and treatment of cancer by nutraceuticals (2004) (51)
Lebectin, a Macrovipera lebetina venom‐derived C‐type lectin, inhibits angiogenesis both in vitro and in vivo (2007) (50)
Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. (2005) (50)
c-Met activation in medulloblastoma induces tissue factor expression and activity: effects on cell migration. (2009) (49)
Impaired tyrosine phosphorylation of membrane type 1-matrix metalloproteinase reduces tumor cell proliferation in three-dimensional matrices and abrogates tumor growth in mice. (2008) (47)
Matrix metalloproteinases and their inhibitors in human pituitary tumors. (1999) (47)
Human vascular endothelial cells with extended life spans: In vitro cell response, protein expression, and angiogenesis (2004) (47)
Sphingosine‐1‐phosphate induces the association of membrane‐type 1 matrix metalloproteinase with p130Cas in endothelial cells (2008) (46)
Modulation of P‐glycoprotein function by sphingosine kinase‐1 in brain endothelial cells (2007) (45)
Development of Biosensors Based on Immobilization of Enzymes in Eastman AQ Polymer Coated with a Layer of Nafion (1990) (45)
Isoform I (mdr3) is the major form of P-glycoprotein expressed in mouse brain capillaries. Evidence for cross-reactivity of antibody C219 with an unrelated protein. (1995) (45)
Demonstration of a novel type of ATP-diphosphohydrolase (EC 3.6.1.5) in the bovine lung. (1993) (44)
A PSP94-derived Peptide PCK3145 inhibits MMP-9 Secretion and Triggers CD44 Cell Surface Shedding: Implication in Tumor Metastasis (2005) (43)
Radiation-inactivation studies on brush-border-membrane vesicles. General considerations, and application to the glucose and phosphate carriers. (1988) (42)
Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma. (2004) (42)
Identification of the cyclosporin-binding site in P-glycoprotein. (1998) (42)
Immunodetection of a type III sodium-dependent phosphate cotransporter in tissues and OK cells. (1998) (41)
Regulation of cytoskeletal functions by Rho small GTP-binding proteins in normal and cancer cells. (1996) (41)
Resveratrol Targeting of Carcinogen-Induced Brain Endothelial Cell Inflammation Biomarkers MMP-9 and COX-2 is Sirt1-Independent (2012) (40)
Subcellular distribution and membrane association of Rho-related small GTP-binding proteins in kidney cortex. (1995) (39)
Effects of perindopril on elastic and structural properties of large arteries in essential hypertension. (2004) (38)
Glycosphingolipids modulate renal phosphate transport in potassium deficiency. (2001) (38)
The diet-derived sulforaphane inhibits matrix metalloproteinase-9-activated human brain microvascular endothelial cell migration and tubulogenesis. (2008) (38)
Kidney ischemia-reperfusion regulates expression and distribution of tubulin subunits, beta-actin and rho GTPases in proximal tubules. (2004) (37)
Inhibition of sphingosine-1-phosphate- and vascular endothelial growth factor-induced endothelial cell chemotaxis by red grape skin polyphenols correlates with a decrease in early platelet-activating factor synthesis. (2006) (37)
Conferone from Ferula schtschurowskiana enhances vinblastine cytotoxicity in MDCK-MDR1 cells by competitively inhibiting P-glycoprotein transport. (2006) (37)
RhoA/ROCK and Cdc42 regulate cell-cell contact and N-cadherin protein level during neurodetermination of P19 embryonal stem cells. (2004) (37)
The Dietary Flavones Apigenin and Luteolin Impair Smooth Muscle Cell Migration and VEGF Expression through Inhibition of PDGFR-β Phosphorylation (2008) (36)
Down‐regulation of caveolin‐1 in glioma vasculature: Modulation by radiotherapy (2004) (36)
Ischemia-reperfusion injury stimulates gelatinase expression and activity in kidney glomeruli. (2005) (35)
Medulloblastoma cell invasion is inhibited by green tea (−)epigallocatechin‐3‐gallate (2003) (32)
Molecular Interactions of Cyclosporin A with P-glycoprotein (1997) (32)
P-glycoprotein of blood brain barrier: cross-reactivity of Mab C219 with a 190 kDa protein in bovine and rat isolated brain capillaries. (1995) (31)
Shark Cartilage Extracts as Antiangiogenic Agents: Smart Drinks or Bitter Pills? (2004) (30)
Expression of melanotransferrin isoforms in human serum: relevance to Alzheimer's disease. (2003) (30)
Immunochemical characterization of L-isoaspartyl-protein carboxyl methyltransferase from mammalian tissues. (1995) (30)
Regulation of brain endothelial cells migration and angiogenesis by P-glycoprotein/caveolin-1 interaction. (2008) (29)
Effect of temperature and pH on phosphate transport through brush border membrane vesicles in rats. (1984) (27)
Palmitoylation of the glucose transporter in blood-brain barrier capillaries. (1995) (27)
Melanotransferrin induces human melanoma SK-Mel-28 cell invasion in vivo. (2007) (26)
Æ-941 (Neovastat®): a novel multifunctional antiangiogenic compound (2001) (26)
Tissue factor pathway inhibitor (TFPI) interferes with endothelial cell migration by inhibition of both the Erk pathway and focal adhesion proteins (2008) (26)
Demonstration of an ectoATP-diphosphohydrolase (E.C.3.6.1.5.) in non-vascular smooth muscles of the bovine trachea. (1994) (25)
P-Glycoprotein Is a Dimer in the Kidney and Brain Capillary Membranes: Effect of Cyclosporin A and SDZ-PSC 833† (1997) (24)
The Antiangiogenic Agent Neovastat (Æ-941) Stimulates Tissue Plasminogen Activator Activity (2004) (24)
Proteomic Analysis of Human Plasma Proteins by Two-Dimensional Gel Electrophoresis and by Antibody Arrays Following Depletion of High-Abundance Proteins (2007) (24)
Purification and characterization of a stimulator of plasmin generation from the antiangiogenic agent Neovastat: identification as immunoglobulin kappa light chain. (2004) (23)
Interaction of immunosuppressive agents rapamycin and its analogue SDZ-RAD with endothelial P-gp. (2002) (23)
Membrane type 1-matrix metalloproteinase induces endothelial cell morphogenic differentiation by a caspase-dependent mechanism. (2005) (23)
Combined low dose ionizing radiation and green tea-derived epigallocatechin-3-gallate treatment induces human brain endothelial cells death (2006) (23)
Brain endothelial cells as pharmacological targets in brain tumors (2004) (23)
VEGF increases the fibrinolytic activity of endothelial cells within fibrin matrices: involvement of VEGFR-2, tissue type plasminogen activator and matrix metalloproteinases. (2007) (23)
Selective modification of coupling factor 1 in spinach chloroplast thylakoids by a fluorescent maleimide. (1983) (22)
Involvement of disulphide bonds in the renal sodium/phosphate co-transporter NaPi-2. (1997) (22)
NaPO4 cotransport type III (PiT1) expression in human embryonic kidney cells and regulation by PTH. (1999) (22)
Tissue factor mediates the HGF/Met-induced anti-apoptotic pathway in DAOY medulloblastoma cells (2010) (22)
Activation of tissue plasminogen activator gene transcription by Neovastat, a multifunctional antiangiogenic agent. (2004) (22)
Light-dependent phosphorylation of thylakoid membrane polypeptides. (1979) (21)
Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling (2006) (21)
Effect of arginine modification on kidney brush-border-membrane transport activity. (1984) (20)
Inhibition of endothelial cell movement and tubulogenesis by human recombinant soluble melanotransferrin: involvement of the u-PAR/LRP plasminolytic system. (2005) (20)
Molecular sizes of amino acid transporters in the luminal membrane from the kidney cortex, estimated by the radiation-inactivation method. (1990) (20)
Drug binding to P‐glycoprotein is inhibited in normal tissues following SDZ‐PSC 833 treatment (1998) (19)
Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface binding. (2006) (19)
Inhibition of Angiogenic Properties of Brain Endothelial Cells by Platelet-Derived Sphingosine-1-Phosphate (2005) (19)
Purification and characterization of a membrane-bound protein carboxyl methyltransferase from rat kidney cortex. (1993) (19)
Reversal of P-glycoprotein-mediated drug efflux by eudesmin from Haplophyllum perforatum and cytotoxicity pattern versus diphyllin, podophyllotoxin and etoposide. (2007) (19)
Modulation of Rho and Cytoskeletal Protein Attachment to Membranes by a Prenylcysteine Analog* (2000) (19)
P-glycoprotein is strongly expressed in brain capillaries. (1993) (19)
Farnesyltransferase inhibitor SCH‐66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration (2005) (18)
Association of cyclophilin A with renal brush border membranes: redistribution by cyclosporine A. (2000) (18)
HCaRG increases renal cell migration by a TGF-α autocrine loop mechanism (2005) (18)
Cisplatin induces renal expression of P-glycoprotein and canalicular multispecific organic anion transporter. (1999) (18)
Inhibition of P-glycoprotein by cyclosporin A analogues and metabolites. (1999) (18)
Differences in multidrug resistance phenotype and matrix metalloproteinases activity between endothelial cells from normal brain and glioma (2003) (18)
Cyclosporin inhibits phosphate transport and stimulates alkaline phosphatase activity in renal BBMV. (1991) (17)
Stimulation of cell surface plasminogen activation by membrane-bound melanotransferrin: a key phenomenon for cell invasion. (2005) (17)
Expression of Matrix Metalloproteinases and Their Inhibitors in Human Brain Tumors (1999) (17)
Calmodulin inhibitors trigger the proteolytic processing of membrane type-1 matrix metalloproteinase, but not its shedding in glioblastoma cells. (2001) (16)
AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. (2001) (16)
Members of the low‐density lipoprotein receptor‐related proteins provide a differential molecular signature between parental and CD133(+) DAOY medulloblastoma cells (2010) (16)
The carboxyl methyltransferase modifying G proteins is a metalloenzyme. (1999) (16)
Multi-element analysis of biological tissues by inductively coupled plasma mass spectrometry: healthy sprague dawley rats (1992) (16)
In vivo inhibition of angiogenesis by a soluble form of melanotransferrin. (2006) (16)
Phosphate uptake by superficial and deep nephron brush border membranes (1984) (15)
Direct-acting fibrinolytic enzymes in shark cartilage extract: potential therapeutic role in vascular disorders. (2005) (15)
Endogenous fluorescence of coupling factor 1 from spinach chloroplasts. (1982) (15)
HCaRG increases renal cell migration by a TGF-alpha autocrine loop mechanism. (2005) (15)
Phosphate transport in capillaries of the blood-brain barrier. (1992) (15)
The sodium gradient induces conformational changes in the renal phosphate carrier. (1987) (14)
Inhibition of membrane-type 1 matrix metalloproteinase tyrosine phosphorylation blocks tumor progression in mice. (2010) (14)
Tyrosine protein kinase activity in renal brush-border membranes. (1992) (14)
Molecular size of the Na+-H+ antiport in renal brush border membranes, as estimated by radiation inactivation. (1988) (14)
Electrogenicity of phosphate transport by renal brush-border membranes. (1988) (13)
Melanotransferrin stimulates t-PA-dependent activation of plasminogen in endothelial cells leading to cell detachment. (2006) (13)
Inhibition of HUVEC tubulogenesis by hederacolchiside-A1 is associated with plasma membrane cholesterol sequestration and activation of the Ha-Ras/MEK/ERK cascade (2004) (13)
The response to brain tumor-derived growth factors is altered in radioresistant human brain endothelial cells (2006) (13)
Modulation of matrix gelatinases and metalloproteinase-activating process in acute kidney rejection (2003) (13)
Pharmacological targeting of β-adrenergic receptor functions abrogates NF-κB signaling and MMP-9 secretion in medulloblastoma cells (2010) (13)
TH1902, a new docetaxel‐peptide conjugate for the treatment of sortilin‐positive triple‐negative breast cancer (2021) (12)
Permeability of the peptidic GH secretagogues hexarelin and EP 51389, across rat jejunum (2001) (12)
Phosphate deprivation induces overexpression of two proteins related to the rat renal phosphate cotransporter NaPi-2. (1996) (12)
Age-related changes in carboxyl methylation of proteins in the kidney (1996) (12)
NaPO(4) cotransport type III (PiT1) expression in human embryonic kidney cells and regulation by PTH. (1999) (12)
Asymmetrical distribution of L-isoaspartyl protein carboxyl methyltransferases in the plasma membranes of rat kidney cortex. (1994) (11)
Complete analysis of the trace elements of the kidney. (1990) (11)
RhoB expression is induced after the transient upregulation of RhoA and Cdc42 during neuronal differentiation and influenced by culture substratum and microtubule integrity. (2001) (11)
Protein tyrosine phosphorylation in normal rat tissues. (1994) (11)
Regulation of Rho protein binding to membranes by rhoGDI: inhibition of releasing activity by physiological ionic conditions. (1999) (11)
Normal molecular size of the Na(+)-phosphate cotransporter and normal Na(+)-dependent binding of phosphonoformic acid in renal brush border membranes of X-linked Hyp mice. (1990) (11)
Regulation of phosphate transport by second messengers in capillaries of the blood-brain barrier. (1992) (10)
Subcellular distribution and guanine nucleotide dependency of COOH-terminal methylation in kidney cortex. (1993) (10)
Different molecular sizes for Na(+)-dependent phosphonoformic acid binding and phosphate transport in renal brush border membrane vesicles. (1990) (10)
Protein car☐yl methylation in kidney brush-border membranes (1991) (10)
Brush border membrane proteins in experimental Fanconi's syndrome induced by 4-pentenoate and maleate. (1992) (10)
Membrane topography of the renal phosphate carrier NaPi-2: limited proteolysis studies. (1999) (10)
Molecular size of the renal sodium/phosphate symporter in native and reconstituted systems. (1992) (10)
Kinetic model for phosphate transport in renal brush-border membranes. (1988) (10)
Fractionation of renal brush border membrane proteins with Triton X-114 phase partitioning. (1991) (9)
pH gradient as an additional driving force in the renal re-absorption of phosphate. (1990) (9)
Molecular size of the functional complex and protein subunits of the renal phosphate symporter. (1994) (9)
Characterization of phosphate binding by alkaline phosphatase in rat kidney brush border membrane (1983) (9)
The renal sodium/phosphate symporters: evidence for different functional oligomeric states. (1996) (9)
Inhibition of tumor growth by a truncated and soluble form of melanotransferrin. (2007) (9)
MT1-MMP expression level status dictates the in vitro action of lupeol on inflammatory biomarkers MMP-9 and COX-2 in medulloblastoma cells (2013) (8)
Immunodetection and characterization of proteins implicated in renal sodium/phosphate cotransport. (1994) (8)
Regulation by GTPγS of Protein Carboxylmethyltransferase Activity in Kidney Brush Border Membranes (1998) (8)
Cytosolic proteins of 21-23 kDa are methylated by kidney cortex membrane-associated C-terminal carboxyl methyltransferases. (1994) (8)
Characterization of essential arginine residues implicated in the renal transport of phosphate and glucose. (1992) (8)
Phosphate transport by capillaries of the blood-brain barrier. (1992) (7)
Identification of membrane-type 1 matrix metalloproteinase tyrosine phosphorylation in association with neuroblastoma progression (2009) (7)
Essential arginine residues in isoprenylcysteine protein carboxyl methyltransferase. (1997) (7)
Thylakoid membrane protein phosphorylation in correlation with photosynthetic membrane activation. (1979) (7)
Inhibition of GTPgammaS-dependent L-isoaspartyl protein methylation by tyrosine kinase inhibitors in kidney. (1999) (7)
P-glycoprotein is a dimer in the kidney and brain capillary membranes: effect of cyclosporin A and SDZ-PSC 833. (1997) (7)
Effect of ischemia-reperfusion on the renal brush-border membrane sodium-dependent phosphate cotransporter NaPi-2. (2001) (7)
Towards a Global Assessment of the Anticancer Properties of Fruits and Vegetables: the Montreal Anticancer Nutrinome Project (2007) (7)
Reconstitution of the renal brush-border membrane sodium/phosphate co-transporter. (1991) (7)
Guanine nucleotides stimulate carboxyl methylation of kidney cytosolic proteins. (1992) (6)
von Hippel‐Lindau tumor suppressor protein stimulation by thrombin involves RhoA activation (2004) (6)
Molecular size of a Na(+)-dependent amino acid transporter in Ehrlich ascites cell plasma membranes estimated by radiation inactivation. (1991) (6)
Phosphate transport in kidneys: effect of transmembrane electrical potential. (1991) (6)
New Peptide-Drug Conjugates for Precise Targeting of SORT1-Mediated Vasculogenic Mimicry in the Tumor Microenvironment of TNBC-Derived MDA-MB-231 Breast and Ovarian ES-2 Clear Cell Carcinoma Cells (2021) (6)
Plasminogen-dependent internalization of soluble melanotransferrin involves the low-density lipoprotein receptor-related protein and annexin II (2007) (5)
The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers (2022) (5)
Radiation-inactivation analysis of the oligomeric structure of the renal sodium/D-glucose symporter. (1997) (5)
Functional size of C-terminal protein carboxyl methyltransferase from kidney basolateral plasma membranes. (1994) (5)
Na+ transport by brush border membrane from rat kidney. (1984) (5)
Guanine nucleotides protect Rho proteins from endogenous proteolytic degradation in renal membranes. (1998) (5)
Tyrosine protein phosphorylation in plasma membranes of rat kidney cortex. (1994) (5)
Molecular study of P-glycoprotein in multidrug resistance using surface plasmon resonance. (1995) (5)
Renal brush border membranes from mice with X-linked hypophosphatemia: protein composition, phosphate binding capacity, and protein kinase activity. (1984) (5)
Stimulation of tPA-dependent provisional extracellular fibrin matrix degradation by human recombinant soluble melanotransferrin. (2006) (4)
Modifications post-traductionnelles des protéines par les lipides (1994) (4)
The renal brush border membrane in man. Protein pattern, inorganic phosphate binding and transport: comparison with other species. (1984) (4)
Kidney brush-border membrane transporters: differential sensitivity to diethyl pyrocarbonate. (1991) (4)
Guanosine 5'-(3-O-Thio)triphosphate stimulates protein carboxyl methylation in cell membranes. (1999) (4)
The renal brush border membrane sodium/sulfate cotransporter functions in situ as a homotetramer. (1996) (4)
Vectorization of proteins across the blood–brain barrier: high transcytosis of melanotransferrin (P97) (2003) (4)
Extraction of brain capillary membrane proteins using Triton X-114. (1994) (3)
Palmitoylation of brain capillary proteins. (1995) (3)
Dietary Prevention of Cancer: Anticancer and Antiangiogenic Properties of Green Tea Polyphenols (2005) (3)
New docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer. (2019) (2)
Inhibition by phenylglyoxal of the sodium-coupled fluxes of glucose and phosphate in renal brush-border membranes. (1988) (2)
Increasing potency and safety of anticancer drugs through sortilin receptor-mediated cancer therapy: A new targeted approach for the treatment of ovarian cancer. (2019) (2)
Transport studies with brush border membrane vesicles: choice of experimental parameters. (1989) (2)
Abstract 3578: New Angiochem-modified doxorubicin with increased brain penetration and efficacy against brain tumors (2010) (2)
Introduction to the Blood–Brain Barrier: Chemotherapy and chemosensitization (1998) (2)
Effect of magnesium on ATP labelling by kidney brush border membrane. (1988) (2)
Sphingosine-1-phosphate induces the association of membrane-type 1 matrix metalloproteinase with p 130 Cas in endothelial cells (2008) (2)
The Antiangiogenic Agent Neovastat ( Æ-941 ) Induces Endothelial Cell Apoptosis 1 (2002) (2)
117 POSTER ANG1005, Paclitaxel conjugated to the angiopep brain transport vector for the treatment of brain cancer: preclinical studies (2008) (2)
Cyclosporin treatment alters protein phosphorylation in kidney membranes. (1994) (2)
The Renal Brush Border Membrane in Man (1984) (2)
The Radiation Inactivation of Membrane Transport Systems (1989) (2)
The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells (2022) (2)
ET-09 : A new drug, ANG1005, a conjugate of Paclitaxel and Angiopep peptide vector able to cross the Blood-Brain Barrier for the treatment of brain cancers. (2008) (2)
Abstract 6362: TH1901, a novel curcumin-peptide conjugate for the treatment of Sortilin-positive (SORT1+) cancer (2020) (1)
Protein carboxyl methylation in kidney brush-border membranes. (1991) (1)
Abstract 4417: Uptake of the new paclitaxel-derivative (ANG1005) by the low-density lipoprotein receptor-related protein1 (LRP1) is related to the aggressive phenotype of glioblastoma cells (2010) (1)
The Strongest Expression of P-Glycoprotein is in the Blood-Brain Barrier (1996) (1)
972. Gene-Modified Human Glioma Cells Producing Soluble Human Plasminogen Kringle 5 Peptide Suppress Brain Tumor Progression (2004) (1)
Influence of temperature on phosphate uptake by renal brush border membrane vesicles. (1984) (1)
Radiation inactivation studies on the sodium-dependent dopamine transporter in canine striatal membranes (1994) (1)
The Blood‐Brain Barrier: Roles of the Multidrug Resistance Transporter P‐Glycoprotein (2007) (1)
Modulation of matrix gelatinases and metalloproteinase‐activating process in acute kidney rejection (2003) (1)
Factors affecting the stability of the renal sodium/phosphate symporter during its solubilization and reconstitution. (1995) (1)
Renal brush border membranes in X-linked hypophosphatemic mice: a study of the protein kinase activity. (1984) (1)
Centromere identity originates in the structure of CENP-A/H4 tetramer itself: a mechanism for aneuploidy (2004) (0)
Compositions and methods for modulating the transport through the blood-brain barrier (2002) (0)
Abstract 1439: Increasing potency of anticancer drugs through SORT1+ technology: A new targeted approach for the treatment of ovarian and endometrial cancers (2021) (0)
MT1-MMP expression level status dictates the in vitro action of lupeol on inflammatory biomarkers MMP-9 and COX-2 in medulloblastoma cells (2012) (0)
Brain metastasis and blood-brain barrier invasion : Involvement of membrane-bound melanotransferrin (2007) (0)
Inhibition of angiogenesis and MMP-9 expression by PCK3145 is mediated through targeting of the Akt signaling pathway (2006) (0)
Aprotininpolypeptider for the transport of a compound across the blood-brain barrier (2005) (0)
Carboxyl Methylation of Proteins in Kidney Membranes: Implications in the Repair of Damaged Proteins and in Signal Transduction (1994) (0)
Richard Béliveau's biography (2007) (0)
Regulation by GTPgammaS of protein carboxylmethyltransferase activity in kidney brush border membranes. (1998) (0)
67 POSTER Membrane-type I matrix metalloproteinase is tyrosine phosphorylated on its cytoplasmic domain: role in in vitro angiogenesis (2006) (0)
HCaRG increases renal cell migration by a TGF- (cid:1) autocrine loop mechanism (2005) (0)
Richard Béliveau's researchs (2007) (0)
Polypeptides of aprotinin for transporting a compound across the blood-brain barrier (2005) (0)
Abstract 1061: Increasing potency of anticancer drugs through Sortilin receptor-mediated cancer therapy: A new targeted approach for the treatment of ovarian cancer (2020) (0)
P-229: Perindopril, pulse wave velocity (PWV), and metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in patients with mild-to-moderate essential hypertension (HT) (2002) (0)
Abstract 1076: The peptide-drug conjugate TH1902 inhibits growth of subcutaneous melanoma xenografts and formation of lung metastases in a syngeneic mouse model (2022) (0)
Peptides antiangiogeniques durables (2000) (0)
Abstract 1313: TH1902, a docetaxel peptide-drug conjugate, shows pre-clinical efficacy in several Sortilin-positive (SORT1+) cancers (2021) (0)
Biographie Richard Béliveau (2007) (0)
Abstract 685: Sortilin receptor-mediated novel cancer therapy: A targeted approach to inhibit vasculogenic mimicry in ovarian and breast cancers (2020) (0)
518 POSTER Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts (2006) (0)
Abstract P3-10-07: Receptor-mediated chemotherapy using a new Docetaxel-peptide conjugate for Sortilin-positive triple-negative breast cancer (2020) (0)
Abstract 4493: Sudocetaxel Zendusortide (TH1902), a peptide-drug conjugate for the treatment of sortilin-positive (SORT1+) TNBC and Her2-positive breast cancers (2023) (0)
HCARG GENE INCREASES MIGRATION POTENTIAL OF KIDNEY CELLS (2004) (0)
Abstract 4737: Resveratrol targeting of carcinogen-induced brain endothelial cell inflammation biomarkers MMP-9 and COX-2 is Sirt1-independent (2012) (0)
Angiopep-1, related connections and their uses (2004) (0)
Soluble human plasminogen kringle 5 domain acts as a 2-pronged anti-cancer agent inhibiting both endothelial cells and tumor-associated macrophages (2005) (0)
ANG1005, a new therapeutic drug able to cross the blood-brain barrier for the treatment of brain cancers. (2008) (0)
AFLUID Decemer 46/6 (1999) (0)
Impaired membrane-type 1 matrix metalloproteinase phosphorylation results in blocking 3D-collagen invasion by tumor cells through cell cycle arrest in G0/G1 phase (2007) (0)
Contacts Richard Béliveau (2011) (0)
Abstract 2910: A novel Sortilin-targeted docetaxel peptide conjugate (TH1902), for the treatment of Sortilin-positive (SORT1+) triple-negative breast cancer (2020) (0)
Cyclosporin-binding proteins in astrocytes and neurons exposed to cyclosporin A and PSC-833 (1998) (0)
147 POSTER A new Taxol delivery system for the treatment of brain primary or metastatic tumors (2006) (0)
Angiopep-1, related compounds and corresponding uses. (2004) (0)
Abstract 5146: Increasing penetration of anticancer drugs through sortilin receptor-mediated cancer therapy: A new targeted and personalized Approach in the treatment of ovarian cancer (2017) (0)
42 POSTER Potent inhibition of glioblastoma growth and angiogenesis by melanotransferrin (2006) (0)
Abstract 1853: TH1902, a SORT1 docetaxel peptide-drug conjugate, inhibits tumor growth of human cancer stem-like cells (CD133+) from both triple-negative breast cancers and ovarian cancers (2022) (0)
Tissue factor pathway inhibitor (TFPI) interferes with endothelial cell migration via ERK parthway and proteins involved in focal complexes (2007) (0)
Abstract 1079: Anti-cancer efficacy of TH1902, a SORT1 docetaxel peptide-drug conjugate, against ovarian and endometrial cancers xenografts alone or in combination with carboplatin (2022) (0)
Anthocyanin-rich berry extracts and epigallocatechin gallate reduce the enhanced invasiveness of estrogen-negative human breast carcinoma cells elicited by serum (2007) (0)
Kinetics of phosphate uptake by brush border membranes (BBM) from superficial and deep cortex. (1984) (0)
A new brain delivery system for therapeutic molecules to treat brain primary or metastatic tumors (2007) (0)
Abstract 4499: The peptide-drug conjugate sudocetaxel zendusortide (TH1902) potentiates anti-tumoral activity of the anti-PD-L1 checkpoint inhibitor and induces immune cell infiltration in a B16-F10 syngeneic melanoma model (2023) (0)

This paper list is powered by the following services:

Other Resources About Richard Béliveau

en.wikipedia.org

What Schools Are Affiliated With Richard Béliveau?

Richard Béliveau is affiliated with the following schools:

Image Attributions

Image Source for Richard Béliveau